We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Silica Microparticles Effectively Transport Anticancer Antibodies

By LabMedica International staff writers
Posted on 01 Jun 2010
Microparticles of porous silica (functionalized mesoporous silica, or FMS) have been used to transport effectively anticancer antibodies that slowed the growth of melanoma tumors in a mouse model.

Investigators at the University of Washington (Seattle, USA) loaded chemically modified silica microparticles to a very high density with antibodies specific to the CTLA4 cell surface protein, which is present on many types of cancer cells including melanoma. More...
The particles were approximately 6 µm to 12 µm in diameter and contained pores of about 30 nm in diameter. The pores were loaded to a super high density of about 0.4 mg − 0.8 mg of antibody per mg of FMS. Chemical modification of the FMS particles guaranteed long-lasting local release of the antibodies at the site of injection.

Results published in the May 3, 2010, online edition of the Journal of the American Chemical Society (JACS) revealed that FMS-anti-CTLA4 antibody injected directly into a mouse melanoma induced much greater and extended inhibition of tumor growth than did the antibody when given systemically or after having been injected into the tumor without microparticle carriers. Microparticle treatment prolonged the lives mice with melanoma. Of five mice that had been treated with particles alone (no antibody), all died within 21 days after treatment. In contrast, of the five mice treated with FMS-antibodies, three survived 21 days, and two were still alive at 34 days, when the experiment ended.

"We want to understand the mechanism, because not much is known about how the slowly leaked antibodies induce changes in the immune system or in the microenvironment of the tumor," said senior author Dr. Karl Erik Hellstrom, professor of pathology at the University of Washington.

Related Links:
University of Washington



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Portable POCT Blood Gas Analyzer
BD100
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.